High metabolic and proliferative rates in cancer cells lead to production of large amounts of H 1 and CO 2 , and as a result, net acid extruding transporters are essential for the function and survival of cancer cells. We assessed protein expression of the Na 1 /H 1 exchanger NHE1, the Na 1 -HCO 2 3 cotransporter NBCn1, and the lactate-H 1 cotransporters MCT1 and 24 by immunohistochemical analysis of a large cohort of breast cancer samples. We found robust expression of these transporters in 20, 10, 4 and 11% of samples, respectively. NHE1 and NBCn1 expression both correlated positively with progesterone receptor status, NHE1 correlated negatively and NBCn1 positively with HER2 status, whereas MCT4 expression correlated with lymph node status. Stable shRNA-mediated knockdown (KD) of either NHE1 or NBCn1 in the MDA-MB-231 triple-negative breast cancer (TNBC) cell line significantly reduced steady-state intracellular pH (pH i ) and capacity for pH i recovery after an acid load. Importantly, KD of any of the three transporters reduced in vivo primary tumor growth of MDA-MB-231 xenografts. However, whereas KD of NBCn1 or MCT4 increased tumor-free survival and decreased in vitro proliferation rate and colony growth in soft agar, KD of NHE1 did not have these effects. Moreover, only MCT4 KD reduced Akt kinase activity, PARP and CD147 expression and cell motility. This work reveals that different types of net acid extruding transporters, NHE1, NBCn1 and MCT4, are frequently expressed in patient mammary tumor tissue and demonstrates for the first time that they promote growth of TNBC human mammary tumors in vivo via distinct but overlapping mechanisms.
Introduction
High metabolic and proliferative rates in cancer cells result in the production of large amounts of CO 2 , H 1 and lactate, which must be extruded to allow cell growth and survival. 1, 2 Cancer cells solve this problem by upregulating net acid extruding transporters. [1] [2] [3] [4] In conjunction with insufficient blood supply and restricted diffusion in solid tumors, this results in acid and lactate accumulation in the tumor microenvironment, whereas intracellular pH (pH i ) is maintained normal or even alkaline. Notably, higher pH i levels enable high rates of cellular proliferation and metabolism and counteract cell death, whereas the acidic extracellular pH (pH e ) favors cell migration and invasion, events necessary for metastatic dissemination (ibid.). Net acid extruding transporters upregulated in cancer cells include the Na 1 /H 1 exchanger NHE1 (SLC9A1), the Na 1 ,HCO lack of knowledge about their relative expression and functional importance in specific cancer types. Our previous studies of small sets of patient tissue samples indicated that both NBCn1 and NHE1 are upregulated at the protein level in human breast cancer tissue compared to normal mammary tissue. 7, 8 Increased expression of an acid extruding protein in cancer cells may be driven by a specific oncogene, as we demonstrated for the upregulation of NBCn1 by HER2. [9] [10] [11] Alternatively, and not mutually exclusive, it could be an evolutionary process driven by the metabolic acid load per se, via selection for the phenotype of increased acid extrusion capacity. 4, 12 An open question with important implications for therapy is the relative contributions of different acid extruding transporters to cancer cell function and thus tumor growth in vivo. Recent work showed that mammary tumor development is delayed in NBCn1 knockout mice compared to that in wildtype littermates. 13 Similarly, knockout of NHE1 delayed xenograft tumor growth of MDA-MB-231 cells in athymic nude mice, 14 in agreement with early studies of the tumorigenic potential of NHE1-devoid rat lung fibroblasts. 15 
MCT1
and MCT4 have also been implicated in in vivo growth of some tumor types. 16 We recently showed that NBCn1, NHE1
and MCT1 contributed to 3D spheroid growth of MCF-7 mammary cancer cells, while spheroid growth of triplenegative breast cancer (TNBC) MDA-MB-231 cells predominantly depended on NHE1. 17 However, the relative importance of the various net acid extruding transporters on mammary tumor growth in vivo is largely unknown. Here, we determined correlations between expression of the NHE1, NBCn1, MCT1 and MCT4 transporters and HER2, estrogen receptor (ER), progesterone receptor (PR) and TNBC status in patient mammary tumor tissue. Furthermore, we directly compared the impact of stable KD of NHE1, NBCn1 or MCT4 on growth of MDA-MB-231 xenografts in NOD-SCID-g mice. NBCn1 and NHE1 expression correlated positively and negatively, respectively, with HER2 status and expression of both transporters correlated positively with PR status. KD of NHE1, NBCn1 or MCT4 reduced in vivo tumor growth of MDA-MB-231 xenografts, and functional studies in vitro pointed to the involvement of at least partially different mechanisms. Our work reveals the subtype-specific, albeit overlapping, expression of acid-base transporters in human mammary cancer. The contributions of multiple transporters for growth of a single tumor type in vivo have important implications for therapy.
Materials and Methods

Antibodies
Antibodies against Akt (#9272), phospho-Akt (Ser473) (#4060), Focal Adhesion Kinase (FAK, #3285), phospho-FAK (Tyr576/577) (#3281), Poly-ADP Ribose Polymerase (PARP, #9542) and pSer807/811-Rb (#9308) were from Cell Signaling Technology (Danvers, MA). Antibodies against NHE1 (#sc-136239) and MCT4 (#sc-50329) were from Santa Cruz Biotechnology (Dallas, TX). Antibodies against CD147 antibody (#MAB972) and p150
Glued (#610473) were from R&D Systems (Minneapolis, MN) and BD Transduction Laboratories (San Jose, CA), respectively. NBCn1 and polyclonal NHE1 (xb-17) antibodies were kind gifts from J. Praetorius, Aarhus University, Denmark and M. Musch, University of Chicago, IL, respectively, and monoclonal NHE1 antibody (4e9) was from Santa Cruz Biotechnology. Vinculin (#V9131), b-actin (#A5441), anti-Mouse (#A1293) and anti-Rabbit (#A3937) alkaline phosphatase-conjugated secondary antibodies were from Sigma-Aldrich (St. Louis, MO), and mouse anti-human Ki-67 (#M7240), anti-mouse (#P0447) and anti-rabbit (#P0448) HRP-conjugated secondary antibodies from Dako (Glostrup, Denmark).
Tissue microarrays (TMAs)
Tissue microarrays of the breast cancer cohort YTMA-49, comprising 670 samples of invasive ductal carcinoma were acquired from Yale University School of Medicine, New Haven, CT. 18 Antibody specificity was carefully validated and dilution titrated using samples positive and negative for each transporter (cell lines (AP-1, MDA-MB-231, HEK-293) with exogenous overexpression or knockdown of NHE1, NBCn1 and MCT4, and the MCT1-negative MDA-MB-231 cells and MCT1-positive MCF-7 cells, grown as 3D spheroids, fixed in PFA, paraffin-embedded and exposed to the same deparaffination and rehydration procedure as the TMAs). TMAs were stained as in ref. 19 , scanned using a Hamamatsu NanoZoomer Scanner, and immunoreactivity scored blinded according to intensity of staining (0-31), with samples considered positive when >10% of tumor cells exhibited staining for that marker. Samples lacking ER, PR and HER2 expression were designated TNBCs.
What's new?
Net acid extruding transporters are critical to the survival of cancer cells, which have high metabolic rates and produce excess acid and lactate. Here, three net acid extruding transporters, NHE1, NBCn1, and MCT4, were found to be expressed in human mammary tumor tissue. Their expression varied according to hormone receptor status. In mice, additional variations were identified following transporter knockdown. NBCn1 or MCT4 loss led to reduced MDA-MB-231 breast tumor cell proliferation and anchorage-independent colony formation, while only MCT4 knockdown decreased cell migration and invasion. The findings offer new insight into the relevance of net acid extruding transporters in breast cancer.
Cell lines and cell culture
MDA-MB-231 cells (ATCC, #HTB-26) were grown in DMEM 1885 (incl. NaHCO 2 3 ) (University of Copenhagen, Panum 22-2-24, #015) supplemented with 10% FBS (Gibco, Waltham, MA), 1% Pen/Strep (Thermo-Fisher, Waltham, MA) and 1% MEM Non-Essential Amino Acids 100X (Gibco). Growth medium for the knockdown cell lines was additionally supplemented with 1 lg/mL Puromycin (Gibco). Cells were grown at 378C, 95% humidity, 5% CO 2 and passaged at a confluence of 80%.
Lentiviral KD of NHE1, NBCn1 and MCT4
Lentiviral KD was performed as in ref. 17 . Mission shRNA bacterial glycerol stocks targeting NHE1 (NM_003047), NBCn1 (NM_003615) and MCT4 (NM_004207) were purchased from Sigma-Aldrich. Envelope plasmid pMD2.G and packaging plasmids pMDLg/pRRE and pRSV-Rev, and pLKO.1 empty vector plasmid were a kind gift from J.B. Hansen, University of Copenhagen. Overnight bacterial cultures were cultivated in ampicillin-containing LB medium and plasmid DNA purified using Nucleobond Xtra Midi EF (Macherey-Nagel, D€ uren, Germany). 2.75 lg purified shRNA plasmid DNA was mixed with 0.75 lg pMD2.G, 0.75 lg pMDLg/pRRE, 0.75 lg pRSV-Rev, 12.5 ll FuGENE HD Transfection reagent (Promega, Madison, WI) and DMEM was added to 250 ll. After 15 min at room temperature (RT), the mixture was added to 70% confluent HEK293T cells in DMEM-1885 without Pen/Strep and incubated overnight. The next day, virus-containing medium was harvested, sterile filtered (0.45 lm) and added to 20% confluent MDA-MB-231 cells along with polybrene (5 mg/mL; SigmaAldrich). Fresh medium was added to the HEK293T cells and transduction repeated the next day. After 24 hr, the transduced MDA-MB-231 cells were reseeded and selection with 1 lg/mL Puromycin (Gibco) started. Medium was changed every 2-3 days and cells were split when needed. A parallel dish of non-transduced MDA-MB-231 cells was killed 100% by Puromycin.
Tumor histology
Fixed tumor tissue was embedded in paraffin and cut into 3 mm sections that were deparaffinized and rehydrated as above and stained with hematoxylin and eosin (HE). Evaluation of tumor histology was performed by an experienced pathologist (blinded for knockdown). Immunofluorescence analysis of Ki-67 in xenograft tumor sections Paraffin sections of the excised tumors were heated at 608C for 20 min and deparaffinized through the following steps: Xylene (2 3 10 min), 99.9% ethanol (2 3 5 min), 96% ethanol (5 min), 70% ethanol (5 min), 50% ethanol (5 min). Sections were washed in water, placed in 0.01 M citrate buffer (Citric acid monohydrate; Sigma-Aldrich, in ddH 2 O, pH 6) and heated to 948C for 2 3 10 min, separated by 20 min at RT. After cooling, sections were washed in PBS, incubated with 0.1% Triton-X 100 in PBS for 5 min, blocked in 5% BSA in PBST (PBS 1 0.1% Tween) for 30-60 min at RT and incubated overnight at 48C with Ki-67 antibody diluted 1:500 in 1% BSA in PBST. Sections were washed in PBST (3 3 5 min), incubated in BSA/PBST for 15 min and fluorophore-conjugated secondary antibody in BSA/PBST for 30 min. Sections were washed in PBST (4 3 5 min) including DAPI, mounted with N-propyl-gallate, sealed and visualized using an Olympus IX83 inverted microscope with an ORCA-flash 4.0 digital camera. Images were processed using ImageJ/Fiji and Adobe Photoshop CS6 version 13.0. For quantification of Ki-67 positive cells, 2 images were acquired in the periphery and 2 in the core, avoiding necrotic areas. Quantification was performed blinded, using Volocity 6.3 image analysis software (PerkinElmer, Waltham, MA). Data are presented as Ki-67/DAPI-positive nuclei.
Mouse tumor xenograft model
Proliferation assay
Proliferation was assessed using an IncuCyte ZOOM LiveCell Analysis System (Essen Bioscience, Ann Arbor, MI). 7,500 cells/well were seeded in octuplicate in a 96-well plate or 60,000 cells/well in triplicate in a 12-well plate. Plates were incubated for at least 72 hr in the IncuCyte. Four images per well (310 magnification) were acquired every 2 hr and phase confluence measured. An exponential growth equation was fitted to data obtained from 16 to 40 hr (logarithmic growth phase) using the Least Squares fit and weighting by 1/Y 2 (GraphPad PRISM 6 software). Individual curves were fitted to each dataset and best-fit values for doubling times are reported.
Soft agar colony-forming assay
Twelve-well plates were coated with a bottom layer of 0.75% agar (Sigma-Aldrich) in DMEM 1885 medium. 2,000 cells were seeded as single cells on top of the bottom layer in a top layer constituting 0.36% agar in DMEM 1885 medium. Plates were incubated at 378C, 95% humidity, 5% CO 2 and representative images were acquired after 4 and 8 weeks using a Nikon light microscope at 310 magnification. For the 8 week images, colonies were stained with 0.005% Crystal Violet (Sigma-Aldrich) for 1.5 hr and washed thoroughly in ddH 2 O prior to microscopy.
Immunoblotting
Immunoblotting was performed as in ref. 17 . In brief, cells were lysed (1% SDS, 10 mM Tris-HCl, 1 mM NaVO 3 , pH 7.5, heated to 958C), homogenized by sonication (PowerMED, Portland, ME) and centrifuged for 5 min at 20,000 g at 48C. Protein content was determined (DC Protein Assay kit, Bio-Rad, Hercules, CA), samples equalized with ddH 2 O, and NuPAGE LDS 4x Sample Buffer (Invitrogen) and dithiothreitol added. Proteins were separated using precast Criterion TGX 10% gels (BioRad, Hercules, CA), Tris/ Glycine SDS buffer (BioRad) and Benchmark ladder (Invitrogen) and transferred to Transblot Turbo nitrocellulose membranes (BioRad). Membranes were stained with Ponceau S (Sigma-Aldrich), blocked (5% nonfat dry milk in TBST (0.01 M Tris/HCl, 0.15 M NaCl, 0.1% Tween 20)), incubated overnight at 48C with primary antibodies, washed in TBST, incubated with HRP-conjugated secondary antibodies, washed in TBST, and developed using Pierce ECL Western Blotting Substrate (Thermo Scientific, Waltham, MA). Band intensities were quantified using UN-SCAN-IT 6.1 (Silk Scientific, Orem, UT) and protein expression normalized to that of the corresponding control.
Measurements of pH i
Measurements of pH i were performed essentially as in refs. 9,10. Briefly, MDA-MB-231 cells seeded in WillCo glassbottom dishes (WillCo Wells, Amsterdam, the Netherlands) were loaded with 2 0 ,7 0 -bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethylester (BCECF-AM, 1.6 mM) in growth medium for 30 min at 378C. Cells were washed once in HCO HEPES, adjusted with NaOH to pH 7.4 at 378C after bubbling with 5% CO 2 /air), placed in a 378C-thermostatted chamber with 5% CO 2 /air and solute perfusion, at the stage of a Nikon Eclipse Ti microscope, and imaged using a 403 oil/1.4 NA objective and EasyRatioPro imaging software (PTI, Birmingham, NJ). Emission was measured at 520 nm with excitation alternating between 440 and 485 nm. Acidification was induced by washout of 20 mM NH 4 Cl after 10 min exposure. Calibration was performed using the high-K 1 / nigericin technique and a 4-point linear calibration curve. Steady-state pH i was determined as the stable pH i value before NH 4 Cl exposure. Maximal acidification did not differ between cell lines. Recovery from acidification was calculated as the slope of the initial, linear part of the recovery curve.
Cell adhesion assay
Ninety-six-well plates were coated with 0.1 mg/mL collagen I (Advanced BioMatrix, Carlsbad, CA) in PBS and pre-blocked with 10 mg/mL Bovine Serum Albumin (Sigma-Aldrich) in PBS. 60,000 cells were seeded per well and incubated 1 hr at 378C with 95% O 2 and 5% CO 2 to allow attachment. The wells were washed gently in PBS and adherent cells were fixed and permeabilized in ice-cold methanol for 30 min. Cells were stained with 0.1% Crystal Violet for 30 min, the dye solubilized in 10% acetic acid (Sigma-Aldrich) and absorbance measured at 570 nm.
Cell migration/invasion assay
Cell invasion assays were performed using 8 lm porous Control-and Matrigel-coated inserts (Corning, Corning, NY) with 10% serum as chemoattractant. Cells were serumstarved for 24 hr and 50,000 cells were seeded in serum-free DMEM-1885 in each insert and incubated for 22 hr at 378C/ 5% CO 2 . After 22 hr, non-invaded/-migrated cells were removed using a wet cotton swab and invaded/migrated cells were fixed and permeabilized in ice-cold methanol for 30 min. Nuclei were stained with 10% Giemsa (Sigma-Aldrich) in Gurr buffer (Life technologies, Waltham, MA) for 30 min and counted manually from 4 fields/insert for each experiment, using an Olympus microscope with 310 magnification.
Statistical analysis
Data are shown as representative images or as means with standard error of means (SEM) or standard deviation (SD) error bars as indicated. Statistical significance for TMA data shown in Figure 1 was assessed using the v 2 test for trend, while the comparisons in Table 1 were performed using Fischer's exact test. One-way analysis of variance (ANOVA) followed by Tukey's or Dunnett's post-test was used to test for significant differences between groups. Kaplan-Meier curves were compared by the Log-rank (Mantel-Cox) test followed by Bonferroni correction for multiple testing (significance level p < 0.0167). Linear or exponential curves were fitted where appropriate using Graphpad Prism 6 software, and best-fit values reported. *, ** and *** denote p < 0.05, 0.01 and 0.001, respectively, unless otherwise specified.
Results
NHE1 and NBCn1 expression correlates with HER2 and PR expression in human breast cancer tissue
To determine their possible association with specific histopathological parameters or breast cancer subtypes, expression of NHE1, NBCn1 and MCT1 and 24 was evaluated by immunohistochemistry (IHC) analysis of a tissue microarray (TMA) comprising 670 invasive breast carcinomas (for TMA details, see Supporting Information Table S1 ). Staining Figure 1a . For all four transporters, staining was most prominent in the membrane region, although some intracellular staining was also observed. Marked NHE1 expression was observed in 131 patients (20%), NBCn1 expression in 70 patients (10%), MCT4 expression in 77 patients (11%) and MCT1 expression only in 30 patients (4%). The correlation between expression of each transporter and overall HER2, ER, PR receptor or TNBC status, is shown in Table 1 . NBCn1 expression was more frequent in HER2 expressing tumors, in congruence with our previous findings. [9] [10] [11] Furthermore, expression of NBCn1 and NHE1 was more frequent in PR expressing than in PR-negative tumors. This relation was substantiated when analyzing the correlation between transporter expression and the degree of HER2 and PR overexpression, whereas, interestingly, NHE1 expression correlated negatively with HER2 status (Fig. 1b) . Finally, MCT4 expression correlated positively with nodal status (Table 1) . Collectively, these data show that NHE1 and NBCn1 are frequently expressed in human breast cancers, substantiate our demonstration of upregulation of NBCn1 expression by HER2 in human breast cancer cell lines, 9,10 confirm previous reports of high MCT1 and 24 expression in breast tumors, [23] [24] [25] and reveal for the first time a correlation of NHE1 and NBCn1 expression with PR expression. We next determined whether transporter expression was associated with patient outcome. Survival analysis over the whole dataset, using Kaplan-Meier survival statistics with significance evaluated by the log-rank test showed that expression of NHE1, NBCn1, MCT1, or MCT4 was associated with overall patient survival, whether analyzed over the entire observation period or censored at 10 year follow-up (Supporting Information Fig. S1 ). To ensure that specific patterns were not lost in overall variation, we performed separate analyses of the TNBC and HER2 overexpressing groups. Analysis of the TNBC group alone showed a pattern similar to that in the full TMA dataset. Similarly, despite the correlation of NBCn1 expression with HER2 status, there was no correlation of NBCn1 expression with survival in HER2 overexpressing patients (Supporting Information Fig. S2 ). Thus, protein expression levels of these transporters did not correlate significantly with patient survival in the data set analyzed.
Stable knockdown of NHE1 and NBCn1, and to a lesser extent MCT4, compromises pH i homeostasis NHE1, NBCn1 and MCT4 have all been implicated in tumor growth in animal models, yet their relative contributions have never been compared. As model system, we chose the TNBC type cell line MDA-MB-231, because of its high glycolytic metabolism, 26 ). Mean KD efficiencies through several passages were approximately 85%, 70% and 70% for NHE1, NBCn1 and MCT4, respectively, compared to empty pLKO.1 vector control (Ctrl). Except for a non-significant increase in NHE1 protein upon NBCn1 KD, no compensatory upregulation was observed (Figs. 2a and 2b) . pH i homeostasis was evaluated by real-time BCECF imaging in presence of CO 2 / HCO 2 3 . Steady-state pH i was about 7.15 in control cells, reduced to about 7.05 in NHE1 and NBCn1 KD cells, and unaffected in MCT4 KD cells (Fig. 2c) . Cellular buffering capacity was unaffected by transporter KD (data not shown). Capacity for recovery after an acid load, assessed using the NH 4 Cl prepulse technique, was significantly reduced in NHE1 and NBCn1 KD cells, and numerically but not significantly reduced in MCT4 KD cells (Figs. 2d and 2e) . Tissue microarrays (TMAs) were stained for expression of the transporters as described in Materials and Methods section. TMAs were scanned and analyzed for transporter expression in a blinded fashion. Two-tailed Fisher's exact test was used to test for significant correlations. Significant associations are bolded. Histopathological parameters of the TMA are illustrated in Supporting Information Table S1 . y, n: yes, no.
KD of NHE1, NBCn1 or MCT4 attenuates tumor growth of MDA-MB-231 xenografts
To study the impact of transporter KD on tumor growth in vivo, the four cell lines were injected subcutaneously into both flanks of six female NSG mice per group (Day 0) and tumor growth was monitored every 2-3 days during a period of 32 days. Notably, tumors developed in all injected flanks, except in the NBCn1 KD group, where only 10 of the 12 possible tumors developed. Tumors were approximately 3-4 mm in diameter by palpation at first detection. Tumor growth was delayed in all of the KD groups, and at termination (Day 32), there was a statistically significant difference in tumor volume between the control group and each KD group (Figs. 3a and 3b) . Apart from the difference in size (confirmed by weighing after excision, Supporting Information Fig. S3a ), the macroscopic appearance of the KD tumors was similar to that of control group tumors (Fig. 3c) . Control-and NHE1 KD tumors developed with an average latency 6 95% CI of 5.8 6 0.9 days, and this was increased to 10.08 6 4.1 days for MCT4 KD tumors (not statistically significant) and 16.5 6 6.8 days for NBCn1 KD tumors (p <0.001) (Fig. 3d) . Because there was no difference in tumorfree survival between control and NHE1 KD tumors, tumor growth rates for these groups are directly comparable, and it can be calculated that NHE1 KD tumors exhibited an approximately 40% slower growth rate than controls ((Vol Ctrl -Vol NHE1 KD )/Vol Ctrl at termination). Inspection of HE-stained sections revealed no obvious differences in tumor histology between groups (Supporting Information Fig. S3b ). Transporter KD was fully preserved at termination of the experiment for NBCn1 and MCT4, and numerically remained at >50% for NHE1 (Supporting Information Figs. S3c and S3d). To evaluate proliferative activity, tumor sections were stained for the proliferation marker Ki-67 (Fig.  3e) . The Ki-67 index (Fig. 3f , % Ki-67 positive cells) was not significantly different between treatment groups.
These results show that KD of NHE1, NBCn1 or MCT4 reduced in vivo tumor growth of MDA-MB-231 xenografts and KD of NBCn1 or MCT4 additionally prolonged tumorfree survival.
In vitro proliferation and anchorage-independent growth are decreased by KD of NBCn1 or MCT4
We next asked whether inherently different cell proliferation rates between the four cell lines might explain the differences in tumor growth rates. Doubling times during logarithmic growth for the NBCn1-and MCT4 KD cell lines were significantly prolonged, to 25 hr and 27 hr compared to that of the control cells (23 hr), whereas there was no statistically significant difference between the control and NHE1 KD cell lines (Figs. 4a and 4b ). Paralleling this, the NBCn1-and MCT4 KD cells formed anchorage-independent colonies that were much smaller than those of control cells, while those formed by the NHE1 KD cells were similar or even slightly larger than those of the control (Fig. 4c, lower panel zoomed  images) . No apparent differences in the number of colonies formed were seen on visual inspection of the wells, suggesting that initial colony formation ability was unaltered by KD of either transporter.
These results show that KD of NBCn1 or MCT4, but not of NHE1, reduced proliferation rates and anchorageindependent colony formation of MDA-MB-231 cells.
MCT4 KD is uniquely associated with reduced cell motility, pAkt and PARP expression
A notable observation from the xenograft experiments was that the abdominal cavities of several mice in the MCT4 KD group contained ascites, which can be a sign of metastatic dissemination to the peritoneal cavity. 27 We therefore asked whether transporter KD affected MDA-MB-231 cell motility. Confirming recent reports, 16, 20 MCT4 KD decreased cell migration through 8 lm porous transwell inserts and invasion through Matrigel-coated inserts (Figs. 5a-5c ). Unexpectedly, KD of NHE1 or NBCn1 had no significant impact on migration and invasion under these conditions. Since cell migration and invasion are dependent on coordinated adhesion, 28 we tested whether cell-substratum adhesion was affected by transporter KD. Adhesion to Collagen I, the most abundant ECM component in breast stroma, 21 was modestly increased upon MCT4 KD (Fig. 5d) . No significant differences in expression of Focal Adhesion Kinase (FAK), active, phosphorylated FAK or vinculin, which are frequently associated with altered adhesion signaling, were noted between cell lines (Supporting Information Fig. S4 ).
In addition to reduced proliferation, the reduced in vivo tumor growth of the KD cell lines could reflect altered apoptosis-and survival signaling. To address this, whole cell lysates were analyzed by Western blotting for PARP, cleavage of which from 116 kDa to 86 kDa is a marker of apoptosis. Confirming the apparent uniqueness of MCT4, expression of both full length and cleaved PARP was markedly decreased in MCT4 KD cells only (Fig. 5e) , as was the level of phosphorylated Akt (pAkt, Fig. 5f ). Finally, consistent with MCT4 being required for trafficking of its chaperone, CD147, to the cell membrane, 22 expression of fully glycosylated CD147 was significantly reduced upon MCT4 KD (Fig. 5g) .
Collectively, these results show that in MDA-MB-231 cells, MCT4 KD reduces motility, increases adhesion and reduces PARP, pAKT and CD147 expression.
Discussion
Dysregulation of acid-base transport is implicated in breast cancer development [1] [2] [3] [4] yet the possible correlation of transporter expression with breast cancer subtypes and the relative contributions of different transporters to tumor growth have so far not been reported.
Here, we demonstrate a positive correlation between expression of NBCn1 and HER2 in patient tissue, corroborating our (defined as time until a tumor was detected) for each group and mean tumor latency 6 95% CI. Day 0 is the day of injection. Kaplan-Meier curves were compared by the Log-rank (Mantel-Cox) test followed by Bonferroni correction for multiple testing as pairwise comparisons of each group against the control was performed. Bonferroni corrected significance level: **p < 0.0017. Mean tumor latencies were compared by one-way ANOVA followed by Dunnett's post-test against Ctrl (pLKO.1), *p < 0.05, **p <0.01, ***p <0.001, respectively. Average tumor growth rates from onset to termination were Ctrl: 346. reports that HER2 and its N-terminally truncated variant p95HER2 upregulate NBCn1 in breast cancer cells in vitro in a manner involving both transcriptional and posttranscriptional mechanisms. [9] [10] [11] 29 Also in line with our previous reports, 9, 29 NHE1 was not upregulated in HER2-positive patients, but in fact showed a modest negative correlation with HER2 status. Furthermore, we identified a positive correlation between PR status and NHE1 and NBCn1 expression in patient tissue, the molecular mechanisms of which are yet to be addressed. Thus, HER2 is likely not the only breast cancer oncogene increasing transporter expression, supporting our previous report of increased NHE1 and NBCn1 expression in patient tumor compared to matched control mammary tissue 7 and underscoring the general relevance of these transporters in a breast cancer setting. Finally, MCT4 expression correlated with nodal status. Previous work has been inconsistent, as tumoral MCT4 expression was an independent prognostic factor for metastasis-free survival in one study of TNBC, 23 whereas the opposite was reported in another. 30 We found no correlation between transporter expression and patient survival for any of the four transporters studied. While it is possible that a larger sample size might have revealed modest differences, we consider this result more likely to reflect the important fact that the pivotal parameter is total net acid extrusion, rather than the expression of a specific transporter. Since the activity of ion transporters is heavily posttranslationally regulated, and there is, to date, no appropriate marker reporting on the activity of these four transporters in fixed tissue (such as the phosphorylation status of a given amino acid), the identification of such markers will be essential for understanding the exact links between acid-base transporters and cancer development. Regardless of this, the fractions of patients with marked expression of NHE1, NBCn1 and/or MCT4 (20%, 10% and 11%, respectively) are in the same range as those of other highly clinically relevant markers (e.g. HER2, BRCA1/2), and warrant further investigation of the mechanisms.
A second key finding of this work is that KD of NHE1, NBCn1 or MCT4 significantly reduced xenograft growth of TNBC MDA-MB-231 cells in immunosuppressed mice. While individual studies have shown the involvement of 
NHE1,
14 NBCn1 13 and MCT4 16 in breast cancer development, ours is the first to directly compare the relative importance of these transporters in in vivo breast cancer development. In contrast to previous work based on full NHE1 knockout, 14 we used an 85% KD of NHE1, which may better mimic a pharmacological treatment in a clinical setting. Under these conditions, NHE1 KD had no impact on the time to detectable tumor onset, but reduced tumor growth rate. NBCn1-and MCT4 KD tumors showed delayed onset and reduced growth rates after onset, the former confirming conclusions from chemically induced mammary tumors in NBCn1 KO mice.
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As MDA-MB-231 cells lack HER2 expression, our work substantiates the notion that NBCn1 is important in breast carcinogenesis irrespective of HER2 status. 7 Interestingly, knockdown of another SLC4A family member, SLC4A9, most likely also a Na 1 -driven, electroneutral HCO 2 3 transporter, 31 was recently shown to reduce MDA-MB-231 spheroid-and xenograft growth, 32 corroborating that TNBC tumor pH homeostasis and growth are supported by an arsenal of net acid extruding proteins, not limited to the ones studied here. It is notable that steady-state pH i was decreased by NHE1 and NBCn1 KD, but not by MCT4 KD, whereas tumor growth was reduced by KD of any of the three transporters. While the relative roles of the transporters in pH i homeostasis may differ in vitro and in vivo, we favor the interpretation that MCT4 KD in the MDA-MB-231 cells, which lack MCT1, compromises lactate efflux so substantially that glycolysis is essentially abrogated, reducing metabolic acid production and thus allowing pH i to be maintained by other net acid extruders (NHE1 and NBCn1). Substantiating this notion, inhibition of metabolism by MCT KD or inhibition has been demonstrated previously by us and others. 33, 34 While an increase in pH i is sufficient to induce dysplasia at least under some conditions, 35 it is also well accepted that at least NHE1 plays additional roles, including scaffolding of signaling components. 36, 37 An important question for future studies is, therefore, whether NHE1 and NBCn1 simply serve to regulate global tumor cell pH i or they additionally play specialized roles, e.g. in the form of localized subcellular pH i regulation or specific effects on signaling events. The role of NHE1 corroborates our recent finding that KD as well as CRISPR/Cas9 knockout of NHE1 reduced in vitro 3D growth of MDA-MB-231 cells. 17 Thus, NHE1 plays an important role for mammary tumor cell growth, in congruence with its important role in several other types of solid tumors including pancreatic 38 and colon 39 cancer. Unexpectedly, in vitro proliferation rates and anchorage-independent growth were reduced by KD of NBCn1 or MCT4, but not of NHE1. While at variance with the role of NHE1 in proliferation demonstrated in other cell lines (ref. 40 , our own unpublished results), this parallels recent work in which NHE1 knockout had no effect on proliferation of MDA-MB-231 cells compared to WT-NHE1-expressing controls. 41 The decreased proliferation rate and decreased anchorageindependent growth in vitro are likely to at least in part underlie the reduced tumor growth of NBCn1 and MCT4 KD cell lines in vivo. For NHE1, our findings suggest that the role of this transporter is more important in the 3D 17 and in vivo (this work) settings than in 2D growth. A similar conclusion was recently reached for bicarbonate transporters. 32 The fundamentally different microenvironment, diffusion distances and cell architecture in these conditions are likely to play central roles. One major factor is tumor hypoxia, which develops within 50-100 mm from the nearest oxygen source, 42 exacerbating dependence on glycolysis and thus on acid extrusion. Another may be the scarce availability of nutrients in poorly vascularized tumor areas, as NHE1 activity was proposed to be stimulated by serum deprivation in breast cancer cells. 43 Hence, it will be important to address the impact of tissue architecture 44 on NHE1 activity in vitro vs. in vivo. Further work should also elucidate the exact molecular mechanisms of reduced tumor growth in vivo, since reduced Ki-67 staining was not detectable under these conditions. Intriguingly, while MCT4 KD reduced tumor growth it had a marked adverse effect on the mice, resulting in ascites accumulation and weight loss. While the mechanisms underlying these apparent systemic effects were not addressed here, MCT4 KD cells were distinct in exhibiting decreased PARP and pAkt levels and -corroborating previous reports 20, 45 decreased migration and invasion. In contrast, KD of NHE1 or NBCn1 had no effect on cell motility. While NHE1 is important for motility of many cells, 46 the lack of NHE1 dependence of migration under serum-replete conditions supports recent work of others, 14 underscoring that the role of this transporter is context-dependent. 
